Chain Antimicrobials raises over half a million Euros to perform pre-clinical trials

The research-based startup, Chain Antimicrobials Oy, got over half a million funding from Business Finland together with an investment from Butterfly Ventures. The company develops antimicrobial-coated medical devices in order to prevent formation of healthcare-associated infections.

“The investment will be used to perform preclinical trials in animal models to test the efficacy and safety of the product. With the investment, we shall take a significant step closer to clinical trials”, CEO, Dr. Tejesvi Mysore says.

Hospital acquired infections (HAIs) are one of the most significant problems that disturb the recovery process after receiving medical treatment in a healthcare facility. The result, for example, is a prolonged hospital stay. The most frequently encountered HAIs are the catheter-associated urinary tract infections (CAUTIs), which are attributed to the use of an indwelling urinary catheter. So far, traditional coatings have had little or no preventive effect on these infections. CAUTI increases morbidity, mortality, healthcare costs, and length of hospital stay.

The product of Chain Antimicrobials inhibits the growth of biofilms on the catheter and is non-toxic, thus potentially reducing problems caused by CAUTIs. It is based on inventions made at the Ecology and Genetics research unit of University of Oulu.

“The antimicrobial peptide inventions transferred from University of Oulu offer us a great position to re-shape antimicrobial markets, as the peptides can kill a vast variety of different microbes, including multiresistant species”, Mysore mentions.

Last updated: 25.6.2019